A polymeric nanocomposite film, composed of PMMA/PVDF and different amounts of CuO NPs, was successfully prepared using the casting method to enhance its electrical conductivity. Various techniques were employed to investigate their physicochemical properties. The addition of CuO NPs causes a noticeable difference in the intensities and locations of vibrational peaks in all bands, confirming the incorporation of CuO NPs inside the PVDF/PMMA. In addition, the broadening of the peak at 2θ = 20.6° becomes more intense with increasing amounts of CuO NPs, confirming the increase in the amorphous characteristic of PMMA/PVDF incorporated with CuO NPs in comparison with PMMA/PVDF. Furthermore, the image of the polymeric structure exhibits a smoother shape and interconnection of pore structure associated with spherical particles that agglomerate and give rise to a web-like organization that becomes a matrix. Increasing surface roughness is responsible for an increasing surface area. Moreover, the addition of CuO NPs in the PMMA/PVDF leads to a decrease in the energy band gap, and further increasing the additional amounts of CuO NPs causes the generation of localized states between the valence and conduction bands. Furthermore, the dielectric investigation shows an increase in the dielectric constant, dielectric loss, and electric conductivity, which may be an indication of an increase in the degree of disorder that confines the movement of charge carriers and demonstrates the creation of an interconnected percolating chain, enhancing its conductivity values compared with that without the incorporation of a matrix.

In this study, a stepwise reaction afforded thiazolidinone-based benzothiazole derivatives 1–15, and the synthesized derivatives were then screened for biological significance and found to be the leading candidates against α-amylase and α-glucosidase enzymes. Almost all derivatives showed excellent to good activity ranging against α-amylase, IC50 = 2.10 ± 0.70 to 37.50 ± 0.70 μM, and α-glucosidase, IC50 = 3.20 ± 0.05 to 39.40 ± 0.80 μM. Some analogues such as 4 (2.40 ± 0.70 and 3.50 ± 0.70 μM), 5 (2.30 ± 0.05 and 4.80 ± 0.10 μM), and 6 (2.10 ± 0.70 and 3.20 ± 0.70 μM) were found with folds better activity than that of the standard drug acarbose (9.10 ± 0.10 and 10.70 ± 0.10 μM), respectively. Moreover, the structure–activity relationship (SAR) has been established for all compounds. A molecular docking study has been carried out to explore the binding interactions against α-amylase and α-glucosidase enzymes.

The 7-quinolinyl-bearing triazole analogs were synthesized (1d–19d) and further assessed in vitro for their inhibitory profile against α-amylase andα-glucosidase. The entire analogs showed a diverse range of activities having IC₅₀ values between 0.80 ± 0.05 µM to 40.20 ± 0.70 µM (α-amylase) and 1.20 ± 0.10 µM to 43.30 ± 0.80 µM (α-glucosidase) under the positive control of acarbose (IC₅₀ = 10.30 ± 0.20 µM) (IC₅₀ = 9.80 ± 0.20 µM) as the standard drug. Among the synthesized scaffolds, seven scaffolds 12d, 10d, 8d, 9d, 11d, 5d, and 14d showed excellent α-amylase and α-glucosidase inhibitory potentials with IC₅₀ values of 4.30 ± 0.10, 2.10 ± 0.10, 1.80 ± 0.10, 1.50 ± 0.10, 0.80 ± 0.05, 5.30 ± 0.20, and 6.40 ± 0.30 µM (against α-amylase) and 3.30 ± 0.10, 2.40 ± 0.10, 1.20 ± 0.10, 1.90 ± 0.10, 8.80 ± 0.20, 7.30 ± 0.40, and 5.50 ± 0.10 µM (against α-glucosidase), respectively, while the remaining 12 scaffolds 19d, 8d, 17d, 16d, 15d, 7d, 4d, 3d, 1d, 2d, 13d and 6 d showed less α-amylase and α-glucosidase inhibitory potentials than standard acarbose but still found to be active. Structure–activity connection studies also showed that scaffolds with electron-withdrawing groups like -Cl, -NO₂, and -F linked to the phenyl ring had higher inhibitory potentials for -amylase and -glucosidase than scaffolds with -OCH₃, -Br, and -CH₃ moieties. In order to better understand their binding sites, the powerful scaffolds 11d and 9d were also subjected to molecular docking studies. The results showed that these powerful analogs provide a number of important interactions with the active sites of both of these targeted enzymes, including conventional hydrogen bonding, pi–pi stacking, pi–sulfur, pi–anion, pi–pi, pi–sigma, T-shaped, and halogen (fluorine). Furthermore, various techniques (spectroscopic), including 1H, ¹³C-NMR, and HREI-MS mass, were used to explore the correct structure of newly afforded hybrid scaffolds based on quinoline-bearing triazole ring.

The current study was conducted to obtain hybrid analogues of indole-based thiadiazole derivatives (1–16) in which a number of reaction steps were involved. To examine their biological activity in the presence of the reference drug Donepezil (0.21 ± 0.12 and 0.30 ± 0.32 M, respectively), the inhibitory potentials of AChE and BuChE were determined for these compounds. Different substituted derivatives showing a varied range of inhibitory profiles, when compared to the reference drug, analogue 8 was shown to have potent activity, with IC50 values for AchE 0.15 ± 0.050 M and BuChE 0.20 ± 0.10, respectively, while other substituted compounds displayed good to moderate potentials. Varied spectroscopic techniques including ¹H, ¹³CNMR and HREI-MS were used to identify the basic skeleton of these compounds. Furthermore, all analogues have a known structure–activity relationship (SAR), and molecular docking investigations have verified the binding interactions of molecule to the active site of enzymes.

In late December 2019, a novel coronavirus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), escaped the animal–human interface and emerged as an ongoing global pandemic with severe flu-like illness, commonly known as coronavirus disease 2019 (COVID-19). In this study, a molecular docking study was carried out for seventeen (17) structural analogues prepared from natural maslinic and oleanolic acids, screened against SARS-CoV-2 main protease. Furthermore, we experimentally validated the virtual data by measuring the half-maximal cytotoxic and inhibitory concentrations of each compound. Interestingly, the chlorinated isoxazole linked maslinic acid (compound 17) showed promising antiviral activity at micromolar non-toxic concentrations. Thoughtfully, we showed that compound 17 mainly impairs the viral replication of SARS-CoV-2. Furthermore, a very promising SAR study for the examined compounds was concluded, which could be used by medicinal chemists in the near future for the design and synthesis of potential anti-SARS-CoV-2 candidates. Our results could be very promising for performing further additional in vitro and in vivo studies on the tested compound (17) before further licensing for COVID-19 treatment.

In the present work, copper oxide nanoparticles have been fabricated by using a biological method. Copper oxide nanoparticles (CuO NPs) have received more attention than other metal oxides due to their distinctive properties and applications. Plant-mediated synthesis of nanoparticles has gained the attention of researchers because of its simple and ecologically sustainable approach. The biosynthesis of CuO NPs included the use of Passiflora edulis leaf extract that acts as a stabilizing and reducing agent. A non-toxic, cost-effective, and ecologically acceptable method was the use of plant leaf extract in the biogenesis of nanoscale materials. UV-vis, SEM, FTIR, and XRD techniques were used to examine the biologically produced copper oxide nanoparticles. The findings of the SEM examination, which gives morphological information, demonstrate that the synthesized NPs have a spherical shape and have an average particle size of between 60 and 65 nm. CuO has been further investigated in the current study as a photo-catalyst in the methylene blue (MB) dye degradation and as an antioxidant in free radical scavenging activities. The decolorization efficiency was approximately 93% after 160 min. Furthermore, CuO nanoparticles were tested for antioxidant performance by scavenging 2, 2-diphenyl-1-picrylhydrazyl hydrate free radicals (DPPH) and evaluated by UV-Vis spectroscopy. The result showed that biologically synthesized CuO NPs can be used as an effective antioxidant. The half maximal inhibitory concentration IC50 of copper oxide nanoparticles was found to be in the range of 0.13–0.20.